Deloitte Suggests Attempts to Move “Beyond the Pill” Successful

Looking ahead to 2016, global consultancy firm Deloitte throws the spotlight on three key issues for pharma companies as they enter the New Year: questions relating to operational excellence; the accelerating move towards outcomes-focused models in healthcare; and continued piloting and roll-out of off-site patient engagement and patient-centric models. Greg Reh, Global Sector Leader, Life Sciences at Deloitte and one of the authors of a “state of the nation” report addressing the outlook for pharma and other elements of the life sciences sector, explains: “The existing regulatory environment, cost pressures, and other drivers increasingly heighten the priority for addressing operational excellence.” He adds: “The way the whole product development lifecycle complexity is managed, I think could have a significant impact on operational costs and effectiveness. There are still too many silos between divisional and functional aspects of the development, commercialization and manufacturing continuum that really introduce a lot of inefficiencies.” Secondly, Reh highlights the move towards outcomes-focused models as an ongoing topic next year: how evidence is generated, how data is shared, how organizations navigate the regulatory barriers around collaboration. Thirdly, he flags opportunities and issues around off-site patient engagement and patient-centric models, an area that has seen significant numbers of pilot projects and some rollout activity. “I think that will...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news